Clinical Trials Logo

Anlotinib clinical trials

View clinical trials related to Anlotinib.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05400070 Active, not recruiting - Lung Cancer Clinical Trials

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

primary purpose:Observe the pathological complete response rate (PCR) of postoperative tumor tissue resection and evaluate the safety of the treatment process.

NCT ID: NCT04213118 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence

ALTER-H-004
Start date: April 23, 2020
Phase: Phase 2
Study type: Interventional

A single-arm, open-label clinical trial to assess the effects and safety of anlotinib hydrochloride combined with transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma(HCC) patients at high risk of post surgery recurrence.

NCT ID: NCT02072031 Active, not recruiting - Anlotinib Clinical Trials

Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma(RCC)

Start date: December 2013
Phase: Phase 2
Study type: Interventional

Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to compare the efficacy and safety profile between Anlotinib and Sunitinib in patients with advanced Renal Cell Carcinoma(RCC).